<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article308</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PRODIGE_4_ACCORD_11" style="display:block; margin-bottom:10px;">PRODIGE 4 ACCORD 11 Original</a></li>
<h2><strong>PRODIGE 4 ACCORD 11</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer". The New England Journal of Medicine. 2011. 364:1817-1825. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with metastatic pancreatic cancer and good performance status, how does FOLFIRINOX compare with gemcitabine in terms of efficacy and safety?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
FOLFIRINOX compared with gemcitabine significantly prolongs survival in patients with metastatic pancreatic cancer who have good performance status, though with increased toxicity.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
FOLFIRINOX, a regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin, was associated with a significant improvement in survival over gemcitabine, the standard treatment for advanced pancreatic cancer, in this study. FOLFIRINOX resulted in a higher response rate and improved progression-free survival but exhibited higher toxicity.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of my knowledge cutoff date in 2023, current oncology guidelines may consider FOLFIRINOX a first-line treatment option for selected patients with metastatic pancreatic cancer and good performance status. However, newer data may have emerged since then.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, randomized, phase 2-3 trial<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
342 patients with metastatic pancreatic adenocarcinoma that had not been previously treated with chemotherapy.<br/>
<br/>
Inclusion Criteria<br/>
- Age 18 years or older<br/>
- Histologically and cytologically confirmed, measurable metastatic pancreatic adenocarcinoma<br/>
- ECOG performance status score of 0 or 1<br/>
- Adequate bone marrow, liver function, and renal function<br/>
<br/>
Exclusion Criteria<br/>
- Age of 76 years or older<br/>
- Non-adenocarcinoma pancreatic cancers<br/>
- Prior radiation for measurable lesions<br/>
- Cerebral metastases<br/>
- History of another major cancer<br/>
- Active infection<br/>
- Chronic diarrhea<br/>
- Clinically significant cardiac disease<br/>
- Pregnancy or breast-feeding<br/>
<br/>
Baseline Characteristics<br/>
- Median age: 61 years<br/>
- Male: 56%<br/>
- Metastases: liver (84%), lung (23%)<br/>
- Performance status 0: 60%<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- FOLFIRINOX: oxaliplatin, irinotecan, fluorouracil, leucovorin every 2 weeks<br/>
- Gemcitabine: weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- Overall survival: 11.1 months with FOLFIRINOX vs 6.8 months with gemcitabine (P&lt;0.001)<br/>
<br/>
Secondary Outcomes<br/>
- Progression-free survival: 6.4 months with FOLFIRINOX vs 3.3 months with gemcitabine (P&lt;0.001)<br/>
- Response rate: 31.6% with FOLFIRINOX vs 9.4% with gemcitabine (P&lt;0.001)<br/>
- Increased toxicity with FOLFIRINOX, including neutropenia and febrile neutropenia<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Increased toxicity associated with FOLFIRINOX may limit its use.<br/>
- The selection of patients with good performance status may not be representative of the general population with metastatic pancreatic cancer.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by the French Ministry of Health, Amgen, and the French National League against Cancer, with drug donations from Sanofi-Aventis and Pfizer. <br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Full protocol, including the statistical analysis plan, available at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
